StockData
NeuroPace Inc logo

NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/3029% above fair value
$8.22+0.02 (+0.24%)

Close on Nov 18, 2026Market cap $282.15MP/E –Yield 0.00%

NeuroPace free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

NeuroPace's free cash flow for the twelve months ending Jun 30, 2026 was -$11.61M. For fiscal 2025 it was -$11.34M. The highest annual figure on record is -$11.34M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.34M–
FY2024Dec 31, 2024-$18.26M–
FY2023Dec 31, 2023-$19.87M–
FY2022Dec 31, 2022-$37.47M–
FY2021Dec 31, 2021-$24.96M–
FY2020Dec 31, 2020-$21.67M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.03M–
Q1 FY2026Mar 31, 2026-$6.02M–
Q4 FY2025Dec 31, 2025$409.00K–
Q3 FY2025Sep 30, 2025-$1.97M–
Q2 FY2025Jun 30, 2025-$2.25M–
Q1 FY2025Mar 31, 2025-$7.52M–
Q4 FY2024Dec 31, 2024-$4.84M–
Q3 FY2024Sep 30, 2024-$1.82M–
Q2 FY2024Jun 30, 2024-$3.96M–
Q1 FY2024Mar 31, 2024-$7.63M–
Q4 FY2023Dec 31, 2023-$3.37M–
Q3 FY2023Sep 30, 2023-$2.31M–
Q2 FY2023Jun 30, 2023-$4.36M–
Q1 FY2023Mar 31, 2023-$9.83M–
Q4 FY2022Dec 31, 2022-$7.95M–
Q3 FY2022Sep 30, 2022-$7.01M–
Q2 FY2022Jun 30, 2022-$10.82M–
Q1 FY2022Mar 31, 2022-$11.70M–
Q4 FY2021Dec 31, 2021-$8.36M–
Q3 FY2021Sep 30, 2021-$4.60M–
Q2 FY2021Jun 30, 2021-$6.03M–
Q1 FY2021Mar 31, 2021-$5.97M–
Q4 FY2020Dec 31, 2020-$6.47M–
Q3 FY2020Sep 30, 2020-$5.43M–
Q2 FY2020Jun 30, 2020-$3.21M–
Q1 FY2020Mar 31, 2020-$6.56M–

More NeuroPace figures

See a number that looks wrong?